Where global strategy meets local execution. Designed to scale biotech innovation.
Biotech innovation moves faster when clinical, regulatory, and business goals are aligned early. JRC’s Integrated Product Development (IPD) model helps your program move seamlessly across geographies and disciplines—turning fragmented capabilities into a unified, value-driven strategy.
Cross-Border Development Strategy
We design clinical and regulatory programs that anticipate cross-region data needs and enable U.S. and APAC dual development.
- U.S. & Asia-Pacific parallel development planning
- China–U.S. data bridging strategies
- Trial sequencing across jurisdictions
- FDA-aligned protocol adaptations from APAC studies
U.S. Localization Enablement
For Asia-based companies entering the U.S., we provide execution frameworks to ensure your program meets FDA, investor, and partner expectations.
- U.S. regulatory and clinical execution adaptation
- PI and KOL engagement strategies
- Bridge study design and coordination
- U.S. data positioning and presentation for BD
Integrated Development Governance
We coordinate scientific and operational contributors across borders for speed, consistency, and quality.
- Joint development governance with client teams
- Program management across regulatory, clinical, and commercial functions
- Milestone-driven execution planning
What Makes Us Different
- A true “bi-directional” team across the U.S. and Asia
- IPD model designed for BD, licensing, and valuation milestones
- Track record supporting both inbound (Asia → U.S.) and outbound (U.S. → Asia) strategies